Skip to main content

Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome

Endocrine volume 48, pages 65–68 (2015)Cite this article

Abstract

Depression is one of the most important mental health problems and a leading cause of disability. Selective serotonin reuptake inhibitors (SSRIs) are considered as first-line therapy for the treatment of depressive symptoms among older adults because of their presumed favorable adverse effect profile. However, they could have deleterious effects on the bone. Evidence from longitudinal, cross-sectional, and prospective cohort studies suggests that the use of antidepressants at therapeutic doses is associated with decreased bone mineral density and increased fracture risk. The association between SSRIs use and fracture risk could potentially differ depending on dose, exposure duration, time of exposure, age, or sex. However, the risk of fracture declined rapidly after discontinuation of use of SSRIs. The evidence now seems sufficient to consider adding SSRIs to the list of medications that contribute to osteoporosis. In practice, assessment of risk factor for osteoporosis or fractures could be made taking into account age, gender, duration, and severity of depression, length of SSRI treatments, and other concurrent risk factors.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. E.S. Paykel, Depression: major problem for public health. Epidemiol. Psichiatr. Soc. 15(1), 4–10 (2006)

    PubMed  Google Scholar 

  2. R.S. Shim, P. Baltrus, J. Ye, G. Rust, Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005–2008. J. Am. Board Fam. Med. 24(1), 33–38 (2011). doi:10.3122/jabfm.2011.01.100121

    Article  PubMed Central  PubMed  Google Scholar 

  3. J. Alonso, M.C. Angermeyer, S. Bernert, R. Bruffaerts, T.S. Brugha, H. Bryson, G. de Girolamo, R. Graaf, K. Demyttenaere, I. Gasquet, J.M. Haro, S.J. Katz, R.C. Kessler, V. Kovess, J.P. Lepine, J. Ormel, G. Polidori, L.J. Russo, G. Vilagut, J. Almansa, S. Arbabzadeh-Bouchez, J. Autonell, M. Bernal, M.A. Buist-Bouwman, M. Codony, A. Domingo-Salvany, M. Ferrer, S.S. Joo, M. Martinez-Alonso, H. Matschinger, F. Mazzi, Z. Morgan, P. Morosini, C. Palacin, B. Romera, N. Taub, W.A. Vollebergh, Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. 190(s420), 21–27 (2004). doi:10.1111/j.1600-0047.2004.00327.x

    Google Scholar 

  4. M. Moore, H.M. Yuen, N. Dunn, M.A. Mullee, J. Maskell, T. Kendrick, Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 339, b3999 (2009). doi:10.1136/bmj.b3999

    Article  PubMed Central  PubMed  Google Scholar 

  5. P. Lockhart, B. Guthrie, Trends in primary care antidepressant prescribing 1995–2007: a longitudinal population database analysis. Br. J. Gen. Pract. 61(590), e565–e572 (2011). doi:10.3399/bjgp11X593848

    Article  PubMed Central  PubMed  Google Scholar 

  6. R. Rizzoli, C. Cooper, J.Y. Reginster, B. Abrahamsen, J.D. Adachi, M.L. Brandi, O. Bruyere, J. Compston, P. Ducy, S. Ferrari, N.C. Harvey, J.A. Kanis, G. Karsenty, A. Laslop, V. Rabenda, P. Vestergaard, Antidepressant medications and osteoporosis. Bone 51(3), 606–613 (2012). doi:10.1016/j.bone.2012.05.018

    Article  CAS  PubMed  Google Scholar 

  7. O. Spigset, B. Martensson, Fortnightly review: drug treatment of depression. BMJ 318(7192), 1188–1191 (1999)

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. E.M. Haney, S.J. Warden, M.M. Bliziotes, Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone 46(1), 13–17 (2010). doi:10.1016/j.bone.2009.07.083

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. P. Ducy, G. Karsenty, The two faces of serotonin in bone biology. J. Cell Biol. 191(1), 7–13 (2010). doi:10.1083/jcb.201006123

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. E.M. Haney, S.J. Warden, Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J. Musculoskelet. Neuronal Interact. 8(2), 133–145 (2008)

    CAS  PubMed  Google Scholar 

  11. S.J. Diem, T.L. Blackwell, K.L. Stone, K. Yaffe, E.M. Haney, M.M. Bliziotes, K.E. Ensrud, Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch. Intern. Med. 167(12), 1240–1245 (2007). doi:10.1001/archinte.167.12.1240

    Article  PubMed  Google Scholar 

  12. L.J. Williams, M.J. Henry, M. Berk, S. Dodd, F.N. Jacka, M.A. Kotowicz, G.C. Nicholson, J.A. Pasco, Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int. Clin. Psychopharmacol. 23(2), 84–87 (2008). doi:10.1097/YIC.0b013e3282f2b3bb

    Article  PubMed  Google Scholar 

  13. E.M. Haney, B.K. Chan, S.J. Diem, K.E. Ensrud, J.A. Cauley, E. Barrett-Connor, E. Orwoll, M.M. Bliziotes, Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med. 167(12), 1246–1251 (2007). doi:10.1001/archinte.167.12.1246

    Article  PubMed  Google Scholar 

  14. R. Ginzburg, E. Rosero, Risk of fractures with selective serotonin-reuptake inhibitors or tricyclic antidepressants. Ann. Pharmacother. 43(1), 98–103 (2009). doi:10.1345/aph.1L264

    Article  PubMed  Google Scholar 

  15. S. Schwan, P. Hallberg, SSRIs, bone mineral density, and risk of fractures—a review. Eur. Neuropsychopharmacol. 19(10), 683–692 (2009). doi:10.1016/j.euroneuro.2009.05.001

    Article  CAS  PubMed  Google Scholar 

  16. V. Rabenda, O. Bruyere, J.Y. Reginster, Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants. Bone 51(4), 674–679 (2012). doi:10.1016/j.bone.2012.07.030

    Article  CAS  PubMed  Google Scholar 

  17. M.S. Bakken, A. Engeland, L.B. Engesaeter, A.H. Ranhoff, S. Hunskaar, S. Ruths, Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 42(4), 514–520 (2013). doi:10.1093/ageing/aft009

    Article  PubMed  Google Scholar 

  18. D. Prieto-Alhambra, H. Petri, J.S. Goldenberg, T.P. Khong, O.H. Klungel, N.J. Robinson, F. de Vries, Excess risk of hip fractures attributable to the use of antidepressants in five European countries and the USA. Osteoporos. Int. 25(3), 847–855 (2014). doi:10.1007/s00198-013-2612-2

    Article  CAS  PubMed  Google Scholar 

  19. C. Moura, S. Bernatsky, M. Abrahamowicz, A. Papaioannou, L. Bessette, J. Adachi, D. Goltzman, J. Prior, N. Kreiger, T. Towheed, W.D. Leslie, S. Kaiser, G. Ioannidis, L. Pickard, L.A. Fraser, E. Rahme, Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos. Int. 25(5), 1473–1481 (2014). doi:10.1007/s00198-014-2649-x

    Article  CAS  PubMed  Google Scholar 

  20. J.J. Gagne, A.R. Patrick, H. Mogun, D.H. Solomon, Antidepressants and fracture risk in older adults: a comparative safety analysis. Clin. Pharmacol. Ther. 89(6), 880–887 (2011). doi:10.1038/clpt.2011.54

    Article  CAS  PubMed  Google Scholar 

  21. G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2012). doi:10.1007/s12020-011-9570-2

    Article  CAS  PubMed  Google Scholar 

  22. J.F. Griffith, H.K. Genant, New advances in imaging osteoporosis and its complications. Endocrine 42(1), 39–51 (2012). doi:10.1007/s12020-012-9691-2

    Article  CAS  PubMed  Google Scholar 

  23. Q. Wu, W. Qu, M.D. Crowell, J.G. Hentz, K.A. Frey, Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies. J. Bone Miner. Res. 28(4), 753–763 (2013). doi:10.1002/jbmr.1813

    Article  PubMed  Google Scholar 

  24. V. Rabenda, D. Nicolet, C. Beaudart, O. Bruyere, J.Y. Reginster, Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos. Int. 24(1), 121–137 (2013). doi:10.1007/s00198-012-2015-9

    Article  CAS  PubMed  Google Scholar 

  25. C.S. Eom, H.K. Lee, S. Ye, S.M. Park, K.H. Cho, Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J. Bone Miner. Res 27(5), 1186–1195 (2012). doi:10.1002/jbmr.1554

    Article  CAS  PubMed  Google Scholar 

  26. L.H. Oderda, J.R. Young, C.V. Asche, G.A. Pepper, Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann. Pharmacother. 46(7–8), 917–928 (2012). doi:10.1345/aph.1Q589

    Article  PubMed  Google Scholar 

  27. J.Y. Reginster, R. Deroisy, I. Paul, M. Hansenne, M. Ansseau, Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas 33(2), 133–137 (1999)

    Article  CAS  PubMed  Google Scholar 

  28. C.V. Phillips, K.J. Goodman, The missed lessons of Sir Austin Bradford Hill. Epidemiol. Perspect. Innov. 1(1), 3 (2004). doi:10.1186/1742-5573-1-3

    Article  PubMed Central  PubMed  Google Scholar 

  29. M.W. van den Brand, S. Pouwels, M.M. Samson, T.P. van Staa, B. Thio, C. Cooper, H.G. Leufkens, A.C. Egberts, H.J. Verhaar, F. de Vries, Use of anti-depressants and the risk of fracture of the hip or femur. Osteopor. Int. 20(10), 1705–1713 (2009). doi:10.1007/s00198-009-0849-6

    Article  CAS  Google Scholar 

  30. P. Vestergaard, D. Prieto-Alhambra, M.K. Javaid, C. Cooper, Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose. Osteoporos. Int. 24(2), 671–680 (2013). doi:10.1007/s00198-012-2043-5

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. J.M. Robine, E. Cambois, W. Nusselder, B. Jeune, H.V. Oyen, C. Jagger, The joint action on healthy life years (JA: EHLEIS). Arch. Public Health 71(1), 2 (2013). doi:10.1186/0778-7367-71-2

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Bât B23, 4000, Liège, Belgium

    Olivier Bruyère & Jean-Yves Reginster

Authors
  1. Olivier Bruyère
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Yves Reginster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivier Bruyère.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bruyère, O., Reginster, JY. Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome. Endocrine 48, 65–68 (2015). https://doi.org/10.1007/s12020-014-0357-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0357-0

Keywords

  • Depression
  • Osteoporosis
  • Fracture
  • Antidepressants
  • Selective serotonin reuptake inhibitors